Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer

MLA

Neeraj Chauhan, et al. “Therapeutic Efficacy of a Novel ΒIII/ΒIV-Tubulin Inhibitor (VERU-111) in Pancreatic Cancer.” Journal of Experimental & Clinical Cancer Research, vol. 38, Jan. 2019. EBSCOhost, https://doi.org/10.1186/s13046-018-1009-7.

APA

Neeraj Chauhan, Bilal Bin Hafeez, Miller Duane D, Vivek K. Kashyap, Wei Li, Subhash C. Chauhan, Saini Setua, Meena Jaggi, Murali M. Yallapu, Prashanth K.B. Nagesh, Qinghui Wang, Pallabita Chowdhury, & Sonam Kumari. (2019). Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Journal of Experimental & Clinical Cancer Research, 38. https://doi.org/10.1186/s13046-018-1009-7

Chicago

Neeraj Chauhan, Bilal Bin Hafeez, Miller Duane D, Vivek K. Kashyap, Wei Li, Subhash C. Chauhan, Saini Setua, et al. 2019. “Therapeutic Efficacy of a Novel ΒIII/ΒIV-Tubulin Inhibitor (VERU-111) in Pancreatic Cancer.” Journal of Experimental & Clinical Cancer Research 38 (January). doi:10.1186/s13046-018-1009-7.